Report: EU should speed up CO2 removal from air to meet climate goals
Climate researchers have advised the European Union to speed up the removal of carbon dioxide (CO2) from the air in a report released on Friday.
In the report, the European Scientific Advisory Board on Climate Change recommends that in addition to drastic emission cuts, removing CO2 from the atmosphere is crucial to stopping global warming, stabilizing the climate and mitigating the worst impacts of climate change.
The EU is committed to achieving net-zero emissions by 2050, and ideally, more CO2 should be removed from the atmosphere than is added.
But with carbon sinks such as forests and soils in the EU continuing to decline and new removal methods slow to be adopted, a strong policy response to boost carbon removal is urgently needed, the Copenhagen-based advisory body warned.
Ottmar Edenhofer, chairman of the advisory board, said: "To achieve its climate targets, the EU must quickly scale up carbon dioxide removals while pursuing deep emissions cuts.
With the right incentives, a dynamic policy mix can speed up innovation and strengthen the EU's position in the global race for cleantech leadership."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Japan's ispace tries lunar touchdown again with Resilience lander
By Kantaro Komiya TOKYO (Reuters) -Japanese company ispace is set to try the lunar touchdown of its uncrewed spacecraft again on Friday two years after its failed inaugural mission, in a bid to become the first company outside the United States to achieve a moon landing. Tokyo-based ispace hopes to join U.S. firms Intuitive Machines and Firefly Aerospace, which have accomplished commercial landings amid an intensifying global race for the moon that includes state-run missions from China and India. Resilience, ispace's second lunar lander, is expected to touch down on Mare Frigoris, a basaltic plain about 900 km (560 miles) from the moon's north pole, at 4:17 a.m. Friday local time (1917 GMT Thursday) following an hour-long descent from lunar orbit, according to the company. In 2023, ispace's first lander crashed into the moon's surface due to inaccurate recognition of its altitude. Software remedies have been implemented, while the hardware design is mostly unchanged in Resilience, the company has said. Resilience carries a four-wheeled rover built by ispace's Luxembourg subsidiary and payloads worth a total of $16 million, including scientific instruments from Japanese firms and a Taiwanese university. If the landing is successful, the 2.3-metre-high lander and the microwave-sized rover will begin 14-day exploration activities until the arrival of a freezing-cold lunar night, including capturing images of regolith, the moon's fine-grained surface material, on a contract with U.S. space agency NASA. Later on Friday, ispace will host a press conference about the outcome of the mission, according to the company. Shares in ispace more than doubled earlier this year on growing investor hopes for the second mission, before calming in recent days. Resilience in January shared a SpaceX rocket launch with Firefly's Blue Ghost lander, which took a faster trajectory to the moon and touched down successfully in March. Intuitive Machines, which last year marked the world's first touchdown of a commercial lunar lander, made its second attempt in March but the lander Athena ended on its side on the lunar surface just as in the first mission. Japan last year became the world's fifth country to achieve a soft lunar landing after the former Soviet Union, the U.S., China and India, when the national Japan Aerospace Exploration Agency (JAXA) achieved the touchdown of its SLIM lander, yet also in a toppled position. Despite President Donald Trump's proposed changes to the U.S. space policy, Japan remains committed to NASA's Artemis moon program, pledging the involvement of Japanese astronauts and technologies for future lunar missions. Including one in 2027 as part of the Artemis program, ispace plans seven more missions in the U.S. and Japan through 2029 to capture increasing demands for lunar transportation.
Yahoo
2 hours ago
- Yahoo
Private Japanese lunar lander heads towards touchdown in the Moon's far north
A private lunar lander from Japan is closing in on the Moon, aiming for a touchdown in the unexplored far north with a mini rover. The Moon landing attempt by Tokyo-based company ispace on Friday Japan time is the latest entry in the rapidly expanding commercial lunar rush. The encore comes two years after the company's first moonshot ended in a crash landing, giving rise to the name Resilience for its successor lander. Resilience holds a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house that will be lowered onto the Moon's dusty surface. Long the province of governments, the Moon became a target of private outfits in 2019, with more flops than wins along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. Deployment of @Firefly_Space's Blue Ghost lunar lander confirmed — SpaceX (@SpaceX) January 15, 2025 It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the Moon faster and became the first private entity to successfully land there in March. Another US company, Intuitive Machines, arrived at the Moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the Moon's south pole and was declared dead within hours. Resilience is targeting the top of the Moon, a less forbidding place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Once settled with power and communication flowing, the 7.5-foot Resilience will beam back pictures, expected several hours or more after touchdown. It will be at least the weekend, according to ispace, before the lander lowers the piggybacking rover onto the lunar surface. Made of carbon fibre-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sports a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for Nasa. The rover, weighing just five kilograms, will stick close to the lander, going in circles at a speed of less than one inch per second. It is capable of venturing up to two-thirds of a mile from the lander and should be operational throughout the two-week mission, the period of daylight. Besides science and tech experiments, there is an artistic touch. The rover holds a tiny, Swedish-style red cottage with white trim and a green door, dubbed the Moonhouse by creator Mikael Genberg, for placement on the lunar surface. Takeshi Hakamada, CEO and founder of ispace, considers the latest moonshot 'merely a stepping stone', with its next, much bigger lander launching by 2027 with Nasa involvement, and even more to follow. 'We're not trying to corner the market. We're trying to build the market,' Jeremy Fix, chief engineer for ispace's US subsidiary, said at a conference last month. 'It's a huge market, a huge potential.' Mr Fix noted that ispace, like other businesses, does not have 'infinite funds' and cannot afford repeated failures. While not divulging the cost of the current mission, company officials said it is less than the first one which exceeded 100 million dollars.
Yahoo
3 hours ago
- Yahoo
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
